Proparco, BII, DEG, FMO & DPI’s investment in Kelix bio’s operations in Egypt and Morocco for USD 200 million

Lead party: British International Investment (BII), Development Partners International (DPI) (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Egypt, Morocco Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity…


Lead party: British International Investment (BII), Development Partners International (DPI) (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Egypt, Morocco

Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity · Deal amount: US$200m · Fund: African Development Partners III (ADP III)

Lead investor/buyer: British International Investment (BII), Development Partners International (DPI) · Investors/buyers: Proparco, Deutsche Investitions-und Entwicklungsgesellschaft (DEG), Netherlands Development Finance Company (FMO), Development Partners International (DPI), British International Investment (BII)

Legal advisers: not identified in the source record.

Source: announced 9 March 2022. Original announcement: proparco.fr.